LopezADMathersCDEzzatiMGlobal and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet. 2006;367:1747–1757.
2.
RushAJTrivediMHWisniewskiSRAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163:1905–1917.
3.
FavaM.Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649–659.
4.
MauskopfJASimonGEKalsekarANonresponse, partial response, and failure to achieve remission: Humanistic and cost burden in major depressive disorder. Depress Anxiety. 2009;26:83–97.
5.
FekaduAWoodersonSCMarkopouloKWhat happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116:4–11.
6.
BerlimMTTureckiG.Definition, assessment, and staging of treatment-resistant refractory major depression: A review of current concepts and methods. Can J Psychiatry. 2007;52:46–54.
7.
FekaduAWoodersonSDonaldsonCA multidimensional tool to quantify treatment resistance in depression: The Maudsley staging method. J Clin Psychiatry. 2009;70:177–184.
8.
WatanabeSIshinoHOtsukiS.Double-blind comparison of lithium carbonate and imipramine in treatment of depression. Arch Gen Psychiatry. 1975;32:659–668.
9.
CutlerAJMontgomerySAFeifelDExtended release quetiapine fumarate monotherapy in major depressive disorder: A placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009;70:526–539.
10.
LamRWKennedySHGrigoriadisSCanadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117(Suppl 1):S26–S43.
11.
ThaseME. Antidepressant combinations: Widely used, but far from empirically validated. Can J Psychiatry. 2011;56(6):317–323.
